The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy.

[1]  G. Jayson,et al.  ZD1839 (Iressa) a selective epidermal growth factor receptor tyrosine kinase inhibitor , 2002 .

[2]  S. Cohen,et al.  Glycosylation-induced Conformational Modification Positively Regulates Receptor-Receptor Association , 2001, The Journal of Biological Chemistry.

[3]  R. Jorissen,et al.  Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor , 2008, Protein science : a publication of the Protein Society.

[4]  S. Ethier,et al.  Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. , 2000, International journal of radiation oncology, biology, physics.

[5]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  B. Neel,et al.  New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway , 2000, Molecular and Cellular Biology.

[7]  M. Fukuoka,et al.  A Phase I intermittent dose-escalation trial of ZD1839 (IressaTM) in Japanese patients with solid malignant tumors , 2000 .

[8]  Bert Vogelstein,et al.  Combinatorial chemoprevention of intestinal neoplasia , 2000, Nature Medicine.

[9]  M. Droller.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 2000, The Journal of urology.

[10]  A. Friedman,et al.  Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Careen K. Tang,et al.  Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. , 2000, Cancer research.

[12]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  I. Lorimer,et al.  Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. , 2000, Journal of immunological methods.

[14]  A. Casamassimi,et al.  EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  L. Norton,et al.  Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Halatsch,et al.  Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. , 2000, Journal of neurosurgery.

[17]  Shigeomi Shimizu,et al.  Bcl‐2 family: Life‐or‐death switch , 2000, FEBS letters.

[18]  E. Olapade-Olaopa,et al.  Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer , 1999, British Journal of Cancer.

[19]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[20]  L. Pustilnik,et al.  Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[21]  R. McLendon,et al.  Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Harari,et al.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[23]  A. Ullrich,et al.  Epidermal growth factor receptors: critical mediators of multiple receptor pathways. , 1999, Current opinion in cell biology.

[24]  R. Todd,et al.  Epidermal growth factor receptor (EGFR) biology and human oral cancer. , 1999, Histology and histopathology.

[25]  G. Tortora,et al.  Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  B. Groner,et al.  Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors , 1999, Oncogene.

[27]  C. Dinney,et al.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  D. Boschelli.  Small molecule inhibitors of receptor tyrosine kinases , 1999 .

[29]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[30]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  I. Lax,et al.  Disulfide Bond Structure of Human Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[32]  H Kijima,et al.  Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. , 1998, Journal of the National Cancer Institute.

[33]  T. Beckers,et al.  Overexpression of EGFR and c‐erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts , 1998, FEBS letters.

[34]  L. Frati,et al.  CD16‐mediated activation of phosphatidylinositol‐3 kinase (Pl‐3K) in human NK cells involves tyrosine phosphorylation of Cbl and its association with Grb2, Shc, pp36 and p85 Pl‐3K subunit , 1998, European journal of immunology.

[35]  M. Antonyak,et al.  Constitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[36]  R. B. Montgomery,et al.  Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[37]  D. Bigner,et al.  The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. , 1998, Journal of neurovirology.

[38]  R. Curnow.  Clinical experience with CD64-directed immunotherapy. An overview , 1997, Cancer Immunology, Immunotherapy.

[39]  L. Pustilnik,et al.  Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. , 1997, Cancer research.

[40]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[41]  D. Bigner,et al.  A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo , 1997, Journal of Neuroimmunology.

[42]  D. Bigner,et al.  Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). , 1997, The Biochemical journal.

[43]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[44]  R. Graziano,et al.  Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. , 1997, Journal of immunology.

[45]  W. Yung,et al.  The autocrine loop of TGF-alpha/EGFR and brain tumors. , 1997, Journal of neuro-oncology.

[46]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[47]  J R Feramisco,et al.  Enhanced Tumorigenic Behavior of Glioblastoma Cells Expressing a Truncated Epidermal Growth Factor Receptor Is Mediated through the Ras-Shc-Grb2 Pathway* , 1996, The Journal of Biological Chemistry.

[48]  W. Cavenee,et al.  Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. , 1996, Cancer research.

[49]  R. B. Montgomery,et al.  Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. , 1996, Oncogene.

[50]  M. Shibuya,et al.  Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. , 1996, British Journal of Cancer.

[51]  N. Ahn,et al.  Induction of Mitogen-activated Protein Kinase Phosphatase 1 by the Stress-activated Protein Kinase Signaling Pathway but Not by Extracellular Signal-regulated Kinase in Fibroblasts (*) , 1996, The Journal of Biological Chemistry.

[52]  Jonathan A. Cooper,et al.  Differential Modulation of Mitogen-activated Protein (MAP) Kinase/Extracellular Signal-related Kinase Kinase and MAP Kinase Activities by a Mutant Epidermal Growth Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[53]  T. Hambuch,et al.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[55]  N. Goldstein,et al.  Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  A. Silvani,et al.  In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. , 1995, British Journal of Cancer.

[57]  P. Humphrey,et al.  Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[58]  M. Willingham,et al.  Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. , 1995, Cancer research.

[59]  W. Cavenee,et al.  EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.

[60]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[61]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[62]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[63]  C. Angeletti,et al.  Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. , 1995, European journal of cancer.

[64]  R. Wagner.  Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[65]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Cohen,et al.  EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor , 1994, Current Biology.

[67]  G. Rodrigues,et al.  Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. , 1994, Oncogene.

[68]  C. Chan,et al.  The intracellular tyrosine kinase domain of the epidermal growth factor receptor undergoes a conformational change upon autophosphorylation. , 1994, The Journal of biological chemistry.

[69]  S. Leon,et al.  Genetic aberrations in human brain tumors. , 1994, Neurosurgery.

[70]  H. Kung,et al.  A complete description of the EGF-receptor exon structure: implication in oncogenic activation and domain evolution. , 1993, Oncogene.

[71]  J. Baselga,et al.  Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.

[72]  D. Bigner,et al.  Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.

[73]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[74]  A. Benabid,et al.  EGF receptor amplification and expression in human brain tumours. , 1992, European journal of cancer.

[75]  G. M. Walton,et al.  Structural analysis of the transmembrane domain of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.

[76]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Hale Jd.  Regulation of epidermal growth factor receptor expression and activation: a brief review. , 1990 .

[78]  J. Haley.  Regulation of epidermal growth factor receptor expression and activation: a brief review. , 1990, Symposia of the Society for Experimental Biology.

[79]  A. Ullrich,et al.  The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. , 1987, Oncogene research.

[80]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.